Who Paid My Doc
David Wheeler
Infectious Disease Annandale, VA Medical Doctor
NPI 1235184318 CMS profile 147303
3289 Woodburn Rd, Suite # 200, Annandale, VA 22003
General payments
$48,669
Research payments
$127,885
Ownership & investment interest
$0
Research they led as principal investigator
$2,026,599
Through program year 2023, David Wheeler of Annandale, VA is reported in the CMS Open Payments database as having received $48,669 across 134 general payments and $127,885 in research payments paid to them. Separately, studies naming them as principal investigator received $2,026,599 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $1,277 | 9 | |
| 2022 | General | $24 | 1 | |
| 2021 | Research | $9,180 | 2 | |
| 2020 | General | $13,230 | 23 | |
| 2020 | Research | $116,961 | 2 | |
| 2019 | General | $34,138 | 101 | |
| 2019 | Research | $1,744 | 19 |
Beside peers
- David Wheeler
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to David Wheeler were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | David Wheeler | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $34,138 | $190 | $60–$862 | $163 |
| 2020 | $13,230 | $124 | $32–$606 | $114 |
| 2021 | $0 | $148 | $38–$905 | $132 |
| 2022 | $24 | $166 | $50–$834 | $149 |
| 2023 | $1,277 | $171 | $57–$787 | $160 |
| 2024 | $0 | $176 | $52–$752 | $164 |
| 2025 | $0 | $188 | $57–$766 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 26 drugsPart D claims
851
Drug cost
$2,161,415
Branded share of claims
77.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | Brand | 89 | $410,620 | |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 86 | $378,922 | |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | Brand | 55 | $257,529 | |
| Descovy Emtricitabine/Tenofov Alafenam | Brand | 77 | $227,511 | |
| Tivicay Dolutegravir Sodium | Brand | 71 | $211,865 | |
| Dovato Dolutegravir Sodium/Lamivudine | Brand | 65 | $200,547 | |
| Prezcobix Darunavir/Cobicistat | Brand | 47 | $132,027 | |
| Juluca Dolutegravir/Rilpivirine | Brand | 23 | $86,413 | |
| Isentress Raltegravir Potassium | Brand | 23 | $84,257 | |
| Triumeq Abacavir/Dolutegravir/Lamivudi | Brand | 12 | $51,631 |
The 10 drugs with the highest cost, of 26 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 36 billing codesPaid by Medicare
$174,868
Medicare patients
509
Services billed
8,720
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 61% | |
| Ischemic heart disease | 50% | |
| Chronic kidney disease | 50% | |
| Diabetes | 45% | |
| Heart failure | 44% | |
| Atrial fibrillation | 37% | |
| Depression | 36% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, ertapenem sodium, 500 mg J1335 | Office | 11 | 101 | $866 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
157 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Infectious Disease in Virginia
Christopher Bettacchi
Infectious Disease · Marion, VA
Stephen Weinroth
Infectious Disease · Fairfax, VA
William Petri
Infectious Disease · Charlottesville, VA
Michael Ison
Infectious Disease · Falls Church, VA
Valerie Riddle
Infectious Disease · Bumpass, VA
Edward Oldfield
Infectious Disease · Norfolk, VA
Related records
Infectious Disease in Virginia
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in Virginia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.